ECSP066883A - Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes - Google Patents

Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes

Info

Publication number
ECSP066883A
ECSP066883A EC2006006883A ECSP066883A ECSP066883A EC SP066883 A ECSP066883 A EC SP066883A EC 2006006883 A EC2006006883 A EC 2006006883A EC SP066883 A ECSP066883 A EC SP066883A EC SP066883 A ECSP066883 A EC SP066883A
Authority
EC
Ecuador
Prior art keywords
diabetes
treatment
heteroarilaminopirazol
derivatives
useful
Prior art date
Application number
EC2006006883A
Other languages
English (en)
Inventor
Joachim Rudolph
Philip Wickens
Chih-Yuan Chuang
Libing Chen
Steven Magnuson
Alan Olague
Ning Qi
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of ECSP066883A publication Critical patent/ECSP066883A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos heteroarilaminopirazólicos, a composiciones farmacéuticas y a métodos para el tratamiento de la diabetes y trastornos relacionados.
EC2006006883A 2004-02-27 2006-09-26 Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes ECSP066883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54833104P 2004-02-27 2004-02-27
US57290604P 2004-05-20 2004-05-20

Publications (1)

Publication Number Publication Date
ECSP066883A true ECSP066883A (es) 2006-11-24

Family

ID=34976070

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006883A ECSP066883A (es) 2004-02-27 2006-09-26 Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes

Country Status (17)

Country Link
US (2) US7517878B2 (es)
EP (1) EP1720863A4 (es)
JP (1) JP2007525513A (es)
KR (1) KR20060124727A (es)
AR (1) AR049418A1 (es)
AU (1) AU2005220723A1 (es)
BR (1) BRPI0508051A (es)
CA (1) CA2557527A1 (es)
EC (1) ECSP066883A (es)
IL (1) IL177232A0 (es)
MA (1) MA28479B1 (es)
NO (1) NO20064325L (es)
PE (1) PE20051159A1 (es)
RU (1) RU2006134004A (es)
TW (1) TW200538130A (es)
UY (1) UY28774A1 (es)
WO (1) WO2005086656A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084214A (zh) 2004-11-17 2007-12-05 迈卡纳治疗股份有限公司 激酶抑制剂
WO2006065590A2 (en) * 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
RU2457207C2 (ru) * 2006-03-24 2012-07-27 Эррэй Биофарма Инк. Активаторы глюкокиназы
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
CA2681695A1 (en) * 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
EP2166849A4 (en) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc SUBSTITUTED PYRAZOL COMPOUNDS
EP2573087A1 (en) 2007-09-21 2013-03-27 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
EP2135865A1 (de) 2008-06-17 2009-12-23 Bayer CropScience AG Substituierte 1-(Diazinyl) pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
EP2194052A1 (de) 2008-12-06 2010-06-09 Bayer CropScience AG Substituierte 1-(Thiazolyl)- und 1-(Isothiazolyl)pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
IL266563B (en) * 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
WO2011073098A1 (de) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
WO2016044666A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Heterocycle substituted amino-pyridine compounds and methods of use thereof
WO2016092559A1 (en) * 2014-12-12 2016-06-16 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives having activity as fungicides
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
KR101725292B1 (ko) * 2016-03-30 2017-04-10 한국과학기술연구원 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체
SMT202100699T1 (it) 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405207A1 (de) * 1994-02-18 1995-08-24 Bayer Ag N-Pyrazolylaniline und N-Pyrazolylaminopyridine
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors

Also Published As

Publication number Publication date
US20050192294A1 (en) 2005-09-01
AU2005220723A1 (en) 2005-09-22
CA2557527A1 (en) 2005-09-22
UY28774A1 (es) 2005-08-31
WO2005086656A2 (en) 2005-09-22
WO2005086656A3 (en) 2005-12-29
AR049418A1 (es) 2006-08-02
KR20060124727A (ko) 2006-12-05
NO20064325L (no) 2006-11-22
JP2007525513A (ja) 2007-09-06
PE20051159A1 (es) 2006-02-22
RU2006134004A (ru) 2008-04-10
US7517878B2 (en) 2009-04-14
TW200538130A (en) 2005-12-01
EP1720863A4 (en) 2009-04-22
IL177232A0 (en) 2006-12-10
BRPI0508051A (pt) 2007-07-17
MA28479B1 (fr) 2007-03-01
US20090209451A1 (en) 2009-08-20
EP1720863A2 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
UY28473A1 (es) Nuevos compuestos
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
EA201070786A1 (ru) Бензофуропиримидиноны
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
IL195030A (en) Dpp iv inhibitor formulations
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
NO20082096L (no) Azaindol-2-karboksamidderivativer
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200626158A (en) Naphthaline derivatives
CR10036A (es) Procedimientos para la preparación de derivados de ciclopropilamida
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
WO2006077024A3 (en) 5-aminoindole derivatives